title: Differential role of cyclooxygenase isozymes on neuronal density in hippocampus CA1 region of intracerebroventricular streptozotocin treated rat brain.
abstract: Intracerebroventricular (ICV) administration of streptozotocin (STZ) causes degeneration of hippocampal neurons through unknown mechanisms that further lead to dementia. On assumption that enzyme cyclooxygenase (COX), which catalyzes the production of pro-inflammatory prostaglandins, may be involved in ICV-STZ induced neurodegeneration, the present study was designed to investigate the effects of chronic treatment with selective inhibitor of COX-1, COX-2 or COX-3 on hippocampal neuronal density in ICV-STZ treated rats. Drugs were administered daily for 21 days, intraperitoneally, in sham control as well as ICV-STZ treated rats. After 21 days of treatment, rats were sacrificed and histological changes were observed in Cornus Ammonis (CA)-1 region of hippocampus at light microscopic level. Histopathological evaluation showed that valeryl salicylate (selective COX-1 inhibitor; 5 and 10 mg/kg; i.p.) and etoricoxib (selective COX-2 inhibitor; 5 and 10 mg/kg; i.p.) significantly increased the survival of hippocampus CA1 neurons in a dose dependent manner. On the contrary, phenacetin (selective COX-3 inhibitor; 20 and 40 mg/kg; i.p.) treatment had no effect on reduced neuronal density in ICV-STZ treated rats. In summary, these findings provide the first comprehensive description about the differential role of COX isozymes in ICV-STZ induced neuronal death in hippocampal CA1 regions of the rat brain.
authors: Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India. neurolife.indian@rediffmail.com
authors: Dinesh K
authors: DK
authors: Dhull
authors: Deepak
authors: D
authors: Bhateja
authors: Rakesh K
authors: RK
authors: Dhull
authors: Satyanarayana S V
authors: SS
authors: Padi
mesh_terms: D000818:Animals; D056547:CA1 Region, Hippocampal / Q000187:drug effects / Q000201:enzymology*; D002470:Cell Survival / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D000077613:Etoricoxib; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000201:enzymology*; D010615:Phenacetin / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012459:Salicylates / Q000494:pharmacology; D013311:Streptozocin / Q000633:toxicity*; D013450:Sulfones / Q000494:pharmacology
chemical_list: D016861:Cyclooxygenase Inhibitors; D011725:Pyridines; D012459:Salicylates; D013450:Sulfones; C117223:valerylsalicylic acid; D013311:Streptozocin; D011451:Prostaglandin-Endoperoxide Synthases; D010615:Phenacetin; D000077613:Etoricoxib